Enhanced CRISPR-Cas9 RNA system delivery using cell penetrating peptides-based nanoparticles for efficient in vitro

Veronica Guzman Gonzalez1, Audrey Grunenberger2, Olivier Nicoud3

  • 1University Grenoble Alpes, INSERM U 1209, CNRS UMR 5309, Cancer Targets and Experimental Therapeutics Team, Institute for Advanced Biosciences, 38000 Grenoble, France.; DivinCell SAS, Nimes, France.

Insights

Novel peptide-based nanoparticles efficiently deliver CRISPR-Cas9 RNA for gene editing. These nanoparticles show promise for in vitro and in vivo applications, overcoming delivery challenges for genetic disease therapies.

Area of Science:

  • Biotechnology
  • Gene Therapy
  • Nanomedicine

Background:

  • CRISPR-Cas9 gene editing holds therapeutic promise for genetic diseases like cancer.
  • Clinical application faces challenges in delivering CRISPR-Cas9 components, particularly RNA, due to degradation and poor cellular uptake.
  • Existing delivery methods struggle with the size, charge, and hydrophilic nature of CRISPR-Cas9 RNA.

Purpose of the Study:

  • To engineer novel peptide-based nanoparticles (ADGN) for efficient delivery of long RNA CRISPR-Cas9 systems.
  • To evaluate the in vitro and in vivo efficacy and targeting capabilities of ADGN nanoparticles for gene editing.

Main Methods:

  • Engineered ADGN peptides to form self-assembled nanoparticles with CRISPR-Cas9 RNA.
  • Assessed nanoparticle cell membrane crossing ability and cancer cell targeting via laminin receptor.
  • Evaluated CRISPR-Cas9 mediated gene knockout efficiency in vitro and in vivo following intravenous administration in mice.

Main Results:

  • ADGN nanoparticles effectively delivered CRISPR-Cas9 RNA, achieving 60% gene knockout efficiency in vitro with a preference for G insertion.
  • Demonstrated successful systemic intravenous administration in mice, leading to effective gene knockout in orthotopic lung tumors.
  • Showed that in vivo distribution of ADGN-RNA is influenced by the peptide-to-RNA molar ratio.

Conclusions:

  • ADGN peptide-based nanoparticles represent a promising new platform for delivering CRISPR-Cas9 RNA systems.
  • These nanoparticles overcome key delivery barriers, enabling efficient gene editing both in vitro and in vivo.
  • The study highlights the potential of ADGN for developing targeted gene therapies for genetic diseases and cancer.